oxynorm 5 mg capsule
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - capsule - oxycodoni hydrochloridum 5 mg corresp. oxycodonum 4.48 mg, cellulosum microcristallinum, magnesii stearas, kapselhülle: e 110 0.02 mg, e 171, e 172 (rubrum), e 132, e 172 (flavum), natrii laurilsulfas corresp. natrium 0.006 mg, gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - un narcotico analgesico - synthetika
oxynorm 10 mg capsule
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - capsule - oxycodoni hydrochloridum 10 mg corresp. oxycodonum 8.97 mg, cellulosum microcristallinum, magnesii stearas, kapselhülle: e 171, e 172 (rubrum), e 132, e 172 (flavum), natrii laurilsulfas corresp. natrium 0.006 mg, gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - un narcotico analgesico - synthetika
oxynorm 20 mg capsule
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - capsule - oxycodoni hydrochloridum 20 mg corresp. oxycodonum 17.93 mg, cellulosum microcristallinum, magnesii stearas, kapselhülle: e 171, e 172 (rubrum), e 132, e 172 (flavum), natrii laurilsulfas corresp. natrium 0.006 mg, gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - un narcotico analgesico - synthetika
oxynorm 5 mg compresse orodispersibili
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - compresse orodispersibili - oxycodoni hydrochloridum 5 mg corresp. oxycodonum 4.48 mg, sacchari sphaerae corresp. saccharum max. 14.14 mg, polyacrylatis dispersio 30 per centum, hypromellosum, mannitolum, silica colloidalis anhydrica, cellulosum microcristallinum, crospovidonum, aspartamum 2.7 mg, aromatica (krauseminze) cum maltodextrinum et menthae spicatae aetheroleum, magnesii stearas, pro compresso. - un narcotico analgesico - synthetika
oxynorm 10 mg compresse orodispersibili
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - compresse orodispersibili - oxycodoni hydrochloridum 10 mg corresp. oxycodonum 8.97 mg, sacchari sphaerae corresp. saccharum max. 28.27 mg, polyacrylatis dispersio 30 per centum, hypromellosum, mannitolum 147.3 mg, silica colloidalis anhydrica, cellulosum microcristallinum, crospovidonum, aspartamum 5.4 mg, aromatica (krauseminze) cum maltodextrinum et menthae spicatae aetheroleum, magnesii stearas, pro compresso. - un narcotico analgesico - synthetika
oxynorm 20 mg compresse orodispersibili
mundipharma medical company, hamilton, bermuda, basel branch - oxycodoni hydrochloridum - compresse orodispersibili - oxycodoni hydrochloridum 20 mg corresp. oxycodonum 17.93 mg, sacchari sphaerae corresp. saccharum max. 56.53 mg, polyacrylatis dispersio 30 per centum, hypromellosum, mannitolum 294.6 mg, silica colloidalis anhydrica, cellulosum microcristallinum, crospovidonum, aspartamum 10.8 mg, aromatica (krauseminze) cum maltodextrinum et menthae spicatae aetheroleum, magnesii stearas, pro compresso. - un narcotico analgesico - synthetika
pantofelan gastroresistenti compresse rivestite con film
g-pharma ag - pantoprazolum - gastroresistenti compresse rivestite con film - pantoprazolum 20 mg ordine pantoprazolum natricum sesquihydricum, mannitolum, natrii carbonas, carboxymethylamylum natricum un copolymerum methacrylatis butylati formano la dieta base, come il calcio stearas, Überzug: acidi methacrylici e ethylis acrylatis polymerisatum 1:1, propylenglycolum, e 172 (giallo), e 171, talco, hypromellosum, macrogolum 400, natrii laurilsulfas, per compresso haze corrisp. sodio max. 4.34 mg. - trattamento a breve termine di refluxsymptomen per adulti - synthetika
clopidogrel almus pharma
almus s.r.l. - clopidogrel - clopidogrel
gefitinib mylan
mylan pharmaceuticals limited - gefitinib - carcinoma, polmone non a piccole cellule - antineoplastic agents, protein kinase inhibitors - gefitinib mylan è indicato come monoterapia per il trattamento di pazienti adulti con carcinoma localmente avanzato o metastatico non a piccole cellule del polmone (nsclc) con mutazioni attivanti dell'egfr‑tk.
oxsynia
mundipharma pharmaceuticals s.r.l. - ossicodone - ossicodone